TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma (clinicaltrials.gov) - Sep 2, 2026 - P2 | N=30 | Not yet recruiting | Sponsor: Brown University | Initiation date: May 2026 ➔ Nov 2026
Trial initiation date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • BCL2 • IRF4
|